Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNPX GENPREX	$0.28 -2.3%	$0.28	$0.20 ▼ $3.97	$9.18M	-0.5	4.21 million shs	841,865 shs
LVTX LAVA Therapeutics	$1.42 +1.4%	$1.32	$0.85 ▼ $2.21	$37.35M	0.48	151,179 shs	23,804 shs
STTK Shattuck Labs	$0.81 +8.6%	$0.97	$0.69 ▼ $4.61	$38.76M	1.63	325,486 shs	129,344 shs
XLO Xilio Therapeutics	$0.72 -0.4%	$0.76	$0.62 ▼ $1.70	$37.39M	-0.15	1.44 million shs	148,396 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNPX GENPREX	0.00%	0.00%	-8.31%	+15.38%	-86.09%
LVTX LAVA Therapeutics	0.00%	+4.41%	+9.57%	+8.40%	-37.99%
STTK Shattuck Labs	0.00%	-0.77%	-16.95%	+4.64%	-82.93%
XLO Xilio Therapeutics	0.00%	-1.65%	+9.29%	-3.94%	-26.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNPX GENPREX	0.7377 of 5 stars	0.0	2.0	4.7	0.6	0.0	0.6
LVTX LAVA Therapeutics	1.4991 of 5 stars	3.0	5.0	0.0	0.6	0.0	0.0
STTK Shattuck Labs	3.6843 of 5 stars	3.4	5.0	0.0	3.2	1.7	1.3
XLO Xilio Therapeutics	1.9723 of 5 stars	3.5	2.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNPX GENPREX	0.00	N/A	N/A	N/A
LVTX LAVA Therapeutics	2.00	Hold	$3.17	123.00% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.50	826.84% Upside
XLO Xilio Therapeutics	3.00	Buy	$4.00	454.02% Upside

Current Analyst Ratings Breakdown

Latest GNPX, STTK, LVTX, and XLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.12	N/A	N/A	$1.06 per share	1.34
STTK Shattuck Labs	$4.61M	8.42	N/A	N/A	$1.67 per share	0.48
XLO Xilio Therapeutics	$6.34M	5.90	N/A	N/A	$0.40 per share	1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-664.65%	-370.18%	8/8/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.39	N/A	N/A	N/A	N/A	-79.69%	-69.13%	7/30/2025 (Estimated)
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	8/14/2025 (Estimated)

Latest GNPX, STTK, LVTX, and XLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/8/2025	N/A	GNPX GENPREX	-$0.71	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	STTK Shattuck Labs	-$0.25	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
5/12/2025	Q1 2025	GNPX GENPREX	-$0.82	-$0.26	+$0.56	-$0.26	N/A	N/A
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNPX GENPREX	N/A	1.94	1.94
LVTX LAVA Therapeutics	N/A	6.73	6.73
STTK Shattuck Labs	N/A	9.08	9.08
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNPX GENPREX	14.05%
LVTX LAVA Therapeutics	N/A
STTK Shattuck Labs	58.74%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
GNPX GENPREX	8.47%
LVTX LAVA Therapeutics	9.50%
STTK Shattuck Labs	12.00%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNPX GENPREX	20	33.15 million	30.34 million	No Data
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	49.09 million	Not Optionable

GNPX, STTK, LVTX, and XLO Headlines

Recent News About These Companies

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants

June 2, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Proposed Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

May 31, 2025 | insidermonkey.com

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer

May 31, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, STTK, LVTX, and XLO Company Descriptions

GENPREX NASDAQ:GNPX

$0.28 -0.01 (-2.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+1.12%)

As of 07/18/2025 07:03 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

LAVA Therapeutics NASDAQ:LVTX

$1.42 +0.02 (+1.43%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$1.42 0.00 (-0.35%)

As of 07/18/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Shattuck Labs NASDAQ:STTK

$0.81 +0.06 (+8.62%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.14%)

As of 07/18/2025 07:50 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Xilio Therapeutics NASDAQ:XLO

$0.72 0.00 (-0.41%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.72 -0.01 (-0.97%)

As of 07/18/2025 07:56 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time